Search research articles
Contact Us
Filters
Showing results (341-350 of 350) with videos related to
Page
of 35
Sort By:
You have reached the last page of results.
This site can display upto 350 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
JAMA Surgery
|
February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Irene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 29, 2009
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma
Annette H Chakera, Birger Hesse, Zeynep Burak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
R V Rawson, C Adhikari, C Bierman, et al.
Nature Medicine
|
February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Cancer Discovery
|
September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
Felicity Newell, Peter A Johansson, James S Wilmott, et al.
JAMA Dermatology
|
April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma
Serigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
The Lancet. Oncology
|
June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
Pathology
|
December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
Richard A Scolyer, Victoria Atkinson, David E Gyorki, et al.
The New England Journal of Medicine
|
June 8, 2017
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B Faries, John F Thompson, Alistair J Cochran, et al.
Page
of 35
Search research articles
Search
Showing results (341-350 of 350) with videos related to
Sort By:
Page
of 35
You have reached the last page of results.
This site can display upto 350 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
JAMA Surgery
|
February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Irene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 29, 2009
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma
Annette H Chakera, Birger Hesse, Zeynep Burak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2021
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
R V Rawson, C Adhikari, C Bierman, et al.
Nature Medicine
|
February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Cancer Discovery
|
September 13, 2022
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
Felicity Newell, Peter A Johansson, James S Wilmott, et al.
JAMA Dermatology
|
April 9, 2025
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma
Serigne N Lo, Caroline Gjorup, Annette Hougaard Chakera, et al.
The Lancet. Oncology
|
June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
Pathology
|
December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
Richard A Scolyer, Victoria Atkinson, David E Gyorki, et al.
The New England Journal of Medicine
|
June 8, 2017
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B Faries, John F Thompson, Alistair J Cochran, et al.
Page
of 35